Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3199 versus formoterol versus placebo in moderate to severe COPD (4-week, phase II)
2009-011265-82Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD3199 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Forced expiratory volume in 1 second (FEV1) maximal bronchodilation and Forced expiratory volume in 1 second (FEV1) trough effect at 24 hours. Started Jul 2009; status: completed.
02
Drugs
AZD3199
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-011265-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011265-82.